News Releases
- November 27, 2023Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
- November 8, 2023Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- November 2, 2023Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
- October 31, 2023Annovis Bio Announces Pricing of $7.5 Million Public Offering
- October 30, 2023Annovis Bio Announces Launch of Proposed Public Offering
- October 30, 2023Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
- October 24, 2023Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
- October 12, 2023Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
- August 15, 2023Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- July 18, 2023Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - October 2023
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top